Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy. Metsera, based in N
(Financial Post, 2025-11-08T17:39:07Z)